Skip to content
Screener

Summit Therapeutics SMMT Net Change in Cash

Net Change in Cash at other companies

Merck & Co. logo
Merck & Co.MRK
-$9.29B-103%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$51M-191%
Nuvation Bio logo
Nuvation BioNUVB
$133.21M-33.4%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$37.44M-41.4%
Incyte logo
IncyteINCY
$521.24M+3,782%

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.79B-49.0%
Enterprise value$10.81B-49.0%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 5:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001599298-26-000039
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from exercise of warrants (3)5,658
Net cash provided by financing activities3,7977,677
Effect of exchange rate changes on cash(19)38
(Decrease) increase in cash, cash equivalents and restricted cash(118,751)106,657
Cash, cash equivalents and restricted cash at beginning of period225,582105,187
Cash, cash equivalents and restricted cash at end of period$106,831$211,844
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$106,515$211,526

Item 1. Financial Statements.

FAQ

What is Summit Therapeutics's net change in cash?
Summit Therapeutics (SMMT) reported net change in cash of -$118.75M in Q1 2026.
How has Summit Therapeutics's net change in cash changed year-over-year?
Summit Therapeutics's net change in cash decreased by 211.3% year-over-year, from $106.66M to -$118.75M.
What is the long-term trend for Summit Therapeutics's net change in cash?
Over 2 years (2022 to 2024), Summit Therapeutics's net change in cash has grown at a -75.8% compound annual growth rate (CAGR), from $576.82M to $33.76M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Summit Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude